The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. - Wikidata - awgldk - TriplyDB

The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease.

The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease.

http://www.wikidata.org/entity/Q44550733

about

Adverse effects of biologics: a network meta-analysis and Cochrane overview Interaction of eosinophils with endothelial cells is modulated by prostaglandin EP4 receptors Lung inflammation caused by inhaled toxicants: a review Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease Muscle function in COPD: a complex interplay Heterogeneity of lung mononuclear phagocytes in chronic obstructive pulmonary disease Advances in understanding COPD Glucocorticoid insensitivity as a future target of therapy for chronic obstructive pulmonary disease What drives the peripheral lung-remodeling process in chronic obstructive pulmonary disease?Differential expression of tissue repair genes in the pathogenesis of chronic obstructive pulmonary disease.Cytokine inhibition in the treatment of COPD.Chronic obstructive pulmonary disease: towards pharmacogenetics.p38 mitogen-activated protein kinase determines the susceptibility to cigarette smoke-induced emphysema in mice.Influencing the decline of lung function in COPD: use of pharmacotherapy.Development and characterization of a long-term murine model of Streptococcus pneumoniae infection of the lower airways.Extracellular superoxide dismutase protects against pulmonary emphysema by attenuating oxidative fragmentation of ECM.Role of th17 cell and autoimmunity in chronic obstructive pulmonary disease.Pharmacological characterisation of anti-inflammatory compounds in acute and chronic mouse models of cigarette smoke-induced inflammation.Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.Compartment differences of inflammatory activity in chronic obstructive pulmonary disease Hypoxemia in patients with COPD: cause, effects, and disease progression Update on pharmaceutical and minimally invasive management strategies for chronic obstructive pulmonary disease.Tumour necrosis factor-α regulates human eosinophil apoptosis via ligation of TNF-receptor 1 and balance between NF-κB and AP-1.A novel nonhuman primate model of cigarette smoke-induced airway disease COPD association and repeatability of blood biomarkers in the ECLIPSE cohort.Novel aspects of pathogenesis and regeneration mechanisms in COPD Systemic inflammatory profile and response to anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease.A Retrospective Longitudinal Within-Subject Risk Interval Analysis of Immunoglobulin Treatment for Recurrent Acute Exacerbation of Chronic Obstructive Pulmonary Disease.Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer.Control of Mycobacterial Infections in Mice Expressing Human Tumor Necrosis Factor (TNF) but Not Mouse TNF.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 Pathological networking: a new approach to understanding COPD.The rs361525 polymorphism does not increase production of tumor necrosis factor alpha by monocytes from alpha-1 antitrypsin deficient subjects with chronic obstructive pulmonary disease - a pilot study.TNF-α is associated with loss of lean body mass only in already cachectic COPD patients Oxidative and Nitrosative Stress and Histone Deacetylase-2 Activity in Exacerbations of COPD.Haemophilus influenzae lysate induces aspects of the chronic obstructive pulmonary disease phenotype Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines Dynamics of pro-inflammatory and anti-inflammatory cytokine release during acute inflammation in chronic obstructive pulmonary disease: an ex vivo study.The TNFalpha gene relates to clinical phenotype in alpha-1-antitrypsin deficiency Update in chronic obstructive pulmonary disease 2006.

P2860

Q24234197-5E86CEF8-B1FF-443C-B8F2-738F23417097 Q24306707-F0EA5AB9-E0B4-4022-8B22-09D27C0C8F2D Q26744356-FC6DD22E-7371-482A-AF61-2BFD03BAB4FC Q26786229-D4842952-BC27-467C-A074-40FD73F9BF6D Q26865732-89AD55ED-C97B-45A8-9246-005ACDD85A57 Q27014453-144AC07C-98EB-42A7-AA54-01E4A26E9129 Q28074701-7126DD94-167D-4701-A19B-188F7F792631 Q28761895-C9095BA2-A5A0-4444-BB0D-1C8731F43D4A Q33518335-71CC9FC1-2D63-4A96-BD32-3DD436E8A151 Q33523967-F8E6F039-41BC-4BE1-B16A-25E8ED6D520E Q33568552-5FEB95FA-56FF-4B70-B62F-36F21260DC9E Q33600138-0506D6EA-969E-4EF0-9A9C-EAB5BA55FCA9 Q33624820-A9CBACDB-E2B3-4249-A841-06720AB3A747 Q33966001-0E988985-D0AB-4C38-B294-CF09C6FACCBA Q34058974-400F7A65-A373-4EAB-8909-68F9480AEC13 Q34100348-96ABA5DC-7136-446F-821E-140B6BA5D252 Q34127425-DA0B67AD-DE6A-4E9C-9DFA-672C3BC207E2 Q34198921-1A9E93C6-A4BC-4F0F-A47C-1E939DCF871E Q34550471-80981A05-3EE1-45ED-B808-DF18BC427B59 Q34570194-B6894956-638A-4C1F-8D76-32F24061145F Q35023212-0A6A9475-E9B1-4CBF-BC8E-21A038EA3BF9 Q35028812-C008506A-EFBF-4AC8-9519-ED801B302021 Q35108937-535F064E-379E-4369-B79B-2FEF31E90830 Q35143749-D28D90E6-EBBD-4082-9C57-540F807C6264 Q35637295-41F368ED-5E71-40F7-8E6D-5D184D897590 Q35665638-FA332CB7-8E57-4C00-BDC1-DDA0A4C0809D Q35779864-6BD384D9-FB3F-47A8-8185-F5F7FE5AF816 Q35838507-3E1FDD39-A614-424E-B7E9-0BFD963B8439 Q35897669-675E1619-770B-4390-B27A-1EC6FC139089 Q35947483-72C00CDE-9E9D-4277-BB25-43A79291D4A2 Q36171750-2E19298F-E1BA-4D1A-B569-BA3993BB0F84 Q36225899-517C30E1-2392-442F-BA3B-E9EED6129583 Q36336165-5D487416-64B1-468C-A2F7-E7B55CC47FF0 Q36367744-ADFDD5AD-94AA-4B67-A657-ABDB1892B786 Q36426923-599A5F66-1D3B-4883-9AB7-7EEB1A346C19 Q36675976-53EFFD96-2428-4B08-B739-52F409577853 Q36724093-5C23F64F-8482-4665-AB60-C7FE0098B13C Q36732429-DADB0A92-22F9-4DAA-8EF1-B44096C411D2 Q36782392-D34C7A37-118E-4B12-8259-736832AEAF1B Q36838782-0E0F1D72-F001-42B9-A142-C855C4593D7E

P2860

The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease.

http://www.wikidata.org/entity/Q44550733

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

The safety and efficacy of inf ...... obstructive pulmonary disease.

@en

The safety and efficacy of inf ...... obstructive pulmonary disease.

@nl

type

label

The safety and efficacy of inf ...... obstructive pulmonary disease.

@en

The safety and efficacy of inf ...... obstructive pulmonary disease.

@nl

prefLabel

The safety and efficacy of inf ...... obstructive pulmonary disease.

@en

The safety and efficacy of inf ...... obstructive pulmonary disease.

@nl

P1433

Q44550733-163422B4-683A-44DE-BF18-8D205B9200F4

P1476

Q44550733-5105035E-CA63-448E-BB9D-06FF7A1F7BCE

P2093

Q44550733-01B0DED5-7777-45D4-BFB7-9123466284A7

Q44550733-087A984E-A430-44AD-B0CB-B953EC0EFE9B

Q44550733-0BC42380-D6F2-4EC9-A736-B0B6A4733AB9

Q44550733-0FB9EE1B-ED1F-4511-BD86-A08C00572C2F

Q44550733-1CE585CC-C0A3-481A-9FF9-557142BDB46A

Q44550733-1F9F1FC5-82D7-4C95-B4B2-87ED9C7B19ED

Q44550733-311B2DA3-5EEF-47F0-89FD-462C5FE9B9EB

Q44550733-35696FF5-57A4-43A2-B2F8-EF13CB70C33E

Q44550733-498728BF-2BFE-45EF-B445-F90CEC33AF9E

Q44550733-5413C9B5-D6B6-4E7B-B66A-AF0AA971AC0F

P2860

Q44550733-05366AF0-33C1-43B9-9D3D-AE8B71C7C506

Q44550733-0E7A7BCA-631E-486D-B2B8-A04918D76900

Q44550733-1768165A-F42B-44A5-9EAF-13353C013DF0

Q44550733-1F4BBF41-C9B5-4BF2-BE8D-48E5F314E056

Q44550733-224B317C-4140-4A9E-8B3A-6D0D2053EF2A

Q44550733-2A96D90A-E315-4A7D-BE42-D05A1CCE86D0

Q44550733-2DD17D4D-AD7F-4791-94BD-27706B45692C

Q44550733-40210E21-9219-41A7-B5AD-D3E898D393A1

Q44550733-4052DAE9-A7D4-49A9-A2C8-E0BDCAAE6E1D

Q44550733-4E828F97-4C00-40C6-AC25-5FF9D0AF00C1

P304

Q44550733-1696DA5B-0647-4F7D-B9BA-59E549A4E839

P31

Q44550733-3F8E488B-07EC-4177-97F5-1F0B7F99C8BB

P356

Q44550733-50C595AF-592C-4201-896A-8B423FE9A4D2

P407

Q44550733-D0B198C5-BF99-439C-B2DC-39D87EFCAD99

P433

Q44550733-82E29347-ACC7-4F03-8D5E-F68379F86A12

P478

Q44550733-1E279ABA-D954-41B1-860E-E03A0FEDFE07

P577

Q44550733-18425C4A-A558-432E-A9D6-D796BE018188

P698

Q44550733-48DC1CEE-63A5-4251-8684-C893C2FEDF4B

P921

Q44550733-E25C9D39-9E19-4402-A3BD-C590AABE3D24

P356

RCCM.200607-995OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

The safety and efficacy of inf ...... obstructive pulmonary disease.

@en

P2093

COPD Investigators

http://www.w3.org/2001/XMLSchema#string

Charles Andrews

http://www.w3.org/2001/XMLSchema#string

Charles Fogarty

http://www.w3.org/2001/XMLSchema#string

Constantine Saadeh

http://www.w3.org/2001/XMLSchema#string

Donald Mahler

http://www.w3.org/2001/XMLSchema#string

Elliot S Barnathan

http://www.w3.org/2001/XMLSchema#string

James Allison

http://www.w3.org/2001/XMLSchema#string

James F Donohue

http://www.w3.org/2001/XMLSchema#string

Joe Ramsdell

http://www.w3.org/2001/XMLSchema#string

John Murray

http://www.w3.org/2001/XMLSchema#string

P2860

The MOS 36-ltem Short-Form Health Survey (SF-36)

Infliximab maintenance therapy for fistulizing Crohn's disease

Standardization of Spirometry, 1994 Update. American Thoracic Society

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

ATS statement: guidelines for the six-minute walk test.

Cellular and structural bases of chronic obstructive pulmonary disease.

Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer.

Tumor necrosis factor or tumor promoting factor?

Cytokines, apoptosis and cachexia: the potential for TNF antagonism.

P304

926-934

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.200607-995OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

175

http://www.w3.org/2001/XMLSchema#string

P577

2007-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17290043

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease